RiverVest Venture Partners is a venture capital firm that specializes in early-stage investments in the healthcare sector. The firm focuses on identifying and nurturing innovative companies that address significant unmet needs in the medical field, particularly in the areas of medical devices, biopharmaceuticals, and healthcare services.

RiverVest Venture Partners

RiverVest Venture Partners® is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors.

With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest accesses forward-thinking research and clinical expertise at leading institutions across the country to found and fund biopharma and medical device companies.

Entrepreneurs turn to RiverVest for the scientific, operational, financial, and investment expertise they need to achieve long-term success. RiverVest is committed to doing business the right way to deliver the best outcomes for patients, entrepreneurs and investors.

Established in 2000, RiverVest has funded more than 60 innovative life science companies and has assets under management of approximately $750 million.  For more information, please visit http://www.rivervest.com.

ZS Pharma

CardiaLen

Lumena Pharmaceuticals

Securus Medical Group

Smart Wires

Spruce Biosciences

Standard Bariatrics

Good Therapeutics

Otonomy

Mirum Pharmaceuticals

Accumetrics

Xilio Therapeutics, Inc.

Allakos

Amplyx Pharmaceuticals

Reneo Pharmaceuticals

RiverVest portfolio company Good Therapeutics, Inc. (now Bonum Therapeutics) is developing a new class of regulated protein therapeutics designed to deliver potent biological activity only where needed. These drugs could be a huge win for patients fighting cancer and other diseases. Roche acquired Good’s PD1-regulated IL-2 program in 2022 for $250 million plus potential milestone payments. We discuss that acquisition and more in RiverVest’s latest case study. Read it at rivervest.com or see a sample below.
 
In this case study, we recognize John Mulligan, Ph.D., Diane Hollenbaugh, John McKearn, the entire team at Bonum Therapeutics, and Roche.
 
Investor Syndicate: Codon Capital, Digitalis Ventures, RiverVest Venture Partners, Roche Venture Fund, and 503 Partners (formerly 3x5 Partners)
 
 #IL2 #PD1 #conditionallyactivetherapeutics #immunooncology #immunotherapy #biotech Neela Patel

At RiverVest, we find and fund innovation to address significant unmet medical needs and improve the lives of patients. During #WorldMitochondrialDiseaseWeek, we recognize the advocacy groups who support research into mitochondrial medicine that will one day lead to treatments and cures for #mito.
 
Read our recent article on the role of patient advocacy groups in drug development here: https://lnkd.in/gm6Sag7A
 
Reneo Pharmaceuticals Niall O'Donnell Wendy Newman Philip Yeske Alison Maguire Ashley H. Danielle Spangler MitoAction Mito Foundation Cure Mito Foundation The PolG Foundation and so many more! 

#MitoAwareness #mitochondrialdisease 

Patient advocacy groups are crucial to the development of drug therapeutics that are most impactful for the patient. For example, patient-derived data often include quality-of-life priorities that researchers don’t anticipate.

In RiverVest's latest "Expert Insight," we explore the role of patient advocacy groups in therapeutic drug development for patients with rare diseases. Learn how one #biopharma company is tackling mitochondrial disease by listening to the experts: the patients and families who live with the disease every day. 

Featured are United Mitochondrial Disease Foundation, Europe's The Lily Foundation, and Reneo Pharmaceuticals.

Niall O'Donnell  Philip Yeske Alison Maguire Wendy Newman Danielle Spangler Gregory J. Flesher Alejandro (Alex) Dorenbaum, M.D. Ashley H.

#raredisease #mito #mitochondrialdisease #PMM #LCFAOD #myopathy

RiverVest portfolio company Xilio Therapeutics, Inc. announced a collaboration with Roche to evaluate XTX101 anti-CTLA4 in combination with Roche’s atezolizumab in patients with microsatellite stable colorectal cancer. 

COM:RIVERVEST

RiverVest Venture Partners